Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Last trade$5.19
Day change-$0.56 (-9.74%)
Day range$5.18 – $5.77
Volume109,010
Market cap$39M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$39M
Price / earnings
—
Price / book
0.36×
Price / sales
17.39×
EV / sales
52.92×
EV / EBITDA
-4.96×
Profitability
Earnings per share
-$3.26
Return on assets
-11.17%
Return on equity
-20.57%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.79×
Current ratio
21.67×
Quick ratio
21.67×
Cash ratio
1.68×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$23.61M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TIL, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
—
$2.24M
$0
$0
$2.77M
$1.49M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
—
$2.24M
$0
$0
$2.77M
$1.49M
Selling, general and administrative
$5.13M
$5.35M
—
$5.9M
$6.16M
$9.11M
$10.37M
$10.71M
Research and development
$270K
$669K
—
$9.13M
$16.74M
$5.37M
$1.1M
$10.56M
Total operating expenses
$5.58M
$7.01M
—
$15.02M
$23.44M
$30.56M
$11.82M
$23.63M
Operating income
-$5.58M
-$7.01M
—
-$12.78M
-$23.44M
-$30.56M
-$9.05M
-$22.14M
Interest expense
-$1.58M
-$1.55M
—
-$1.58M
-$1.58M
-$1.1M
-$3M
-$2.01M
Income before taxes
-$4.3M
-$4.2M
—
-$13.59M
-$21.39M
-$28.2M
-$11.9M
-$23.02M
Income taxes
$0
$0
—
$0
$0
$0
$0
$0
Net income
-$4.3M
-$4.2M
—
-$13.59M
-$21.39M
-$28.2M
-$11.9M
-$23.02M
Net income attributable to common shareholders
-$4.3M
-$4.2M
—
-$13.59M
-$21.39M
-$28.2M
-$11.9M
-$23.02M
EBITDA
-$5.15M
-$6.01M
$12K
-$12.77M
-$22.89M
-$13.98M
-$7.96M
-$18.88M
Basic earnings per share
-$0.63
-$0.62
—
-$2.01
-$3.24
-$4.32
-$1.82
-$3.54
Diluted earnings per share
-$0.63
-$0.62
—
-$2.01
-$3.24
-$4.32
-$1.82
-$3.54
Recent news
Company coverage with links to the original publishers.
Instil Bio (Nasdaq: TIL) reported Q1 2026 results with a cash position of $74.7 million, sufficient to fund operations beyond 2027. The company is actively evaluating acquisition and in-licensing opportunities to build its pipeline. R&D expenses decreased to $0.7 million from $5.4 million year-over-year, while net loss per share improved to $0.62 from $4.32.
Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in First Solar, Instil Bio, and Corcept Therapeutics. First Solar's stock fell 10.29% on January 7, 2026, following a Jefferies downgrade to Hold due to lowered guidance, significant de-bookings, margin compression, and limited deployment opportunities expected in 2026.
Pomerantz LLP announced investigations into securities fraud claims on behalf of investors in three biotech companies. Zenas BioPharma's stock plummeted 51.86% following disappointing Phase 3 trial results for obexelimab, with the CEO acknowledging the drug's efficacy fell short of expectations, triggering an additional 8.49% decline. Similar investigations were initiated for Instil Bio and Corcept Therapeutics.
Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in AST SpaceMobile, Instil Bio, and Corcept Therapeutics. The investigation into AST was triggered by a Scotiabank downgrade to Sell on January 7, 2026, citing competition from SpaceX's Starlink, slow customer adoption, and satellite launch delays. AST's stock fell 12.06% following the downgrade.
Instil Bio reported a wider loss in Q2 2025, with Non-GAAP EPS of $(2.88), missing analyst expectations. The company increased R&D spending to $6.7 million and received FDA clearance for its lead drug candidate '2510, with plans to launch a U.S. clinical trial before year-end.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.